Expression Analysis, a leading provider of genomic services for clinical trials and research, announced that it has expanded its sequencing services to include single-lane sequencing with guaranteed turn-around-times and, firm fixed pricing.
Merck KGaA announced data presented that showed that patients with KRAS wild-type metastatic colorectal cancer who experienced early tumor shrinkage during first-line Erbitux-based treatment lived a median of 28.3 months.
Prosensa received a £7.5m milestone payment from GlaxoSmithKline as a result of achieving a data milestone in its Phase 2a open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy.
Drugmaker Alkermes Inc. said it has received U.S. approval to market its addiction medication for use in patients addicted to narcotics like heroin and morphine.
Health officials in South Africa said they recommend screening all HIV patients for tuberculosis and want automatic TB tests for HIV patients to become normal procedure within five years.
Biogen Idec’s BG-12 is an oral formulation of dimethyl fumarate. This is the first compound in clinical trials to activate the Nrf2 transcriptional pathway, a central mechanism of cellular defense against oxidative and metabolic stress.
Stem cells have the potential to treat a broad range of human disorders. While approaches based on embryonic stem cells and induced pluripotent stem cells have attracted the most media attention, they are complicated by specific challenges.
The glutamate receptor subtype known as N-methyl-D-aspartic acid (NMDA) plays a central role in modulating aspects of brain activity. Naurex is developing a pipeline that modulates the NMDA receptor (NMDAR) at the glycine site.
Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes. Despite its rich therapeutic potential, the glutamatergic system has historically been a challenge for drug discoverers.
A major challenge for Alzheimer’s disease drug candidates, particularly for therapeutic antibodies, is the blood-brain barrier. Once considered impermeable for large molecules, recent evidence has shown that they are in fact able to pass through.
Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes.
Newer treatments for age-related macular degeneration do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies.
A greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor, achieved 75% or better skin clearance rates than those treated with etanercept, methotrexate, or placebo.
Merck KGaA has notified the European Medicines Agency of its intention to request a re-examination of the opinion issued by the Committee for Medicinal Products for Human Use regarding Cladribine Tablets for relapsing-remitting multiple sclerosis.